Information Provided By: 
Fly News Breaks for July 30, 2015
MDVN
Jul 30, 2015 | 07:52 EDT
Stifel cut its price target on Medivation as the firm predicts that prescriptions of the company's Xtandi drug rose only 12% in Q2 versus Q1, producing EPS of 40c versus the consensus estimate of 47c. However, the firm still expects Xtandi to become an important drug in the pre-chemotherapy setting. It keeps a Buy rating on the shares.
News For MDVN From the Last 2 Days
There are no results for your query MDVN
